Torin 2 |
Catalog No.GC13858 |
Torin 2 est un inhibiteur de mTOR avec EC50 de 0,25 nM pour inhiber l'activité mTOR cellulaire et présente une sélectivité de 800 fois par rapport À PI3K (EC50: 200 nM). Torin 2 inhibe également l'ADN-PK avec une CI50 de 0,5 nM dans le test acellulaire. Torin 2 peut supprimer À la fois mTORC1 et mTORC2.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1223001-51-1
Sample solution is provided at 25 µL, 10mM.
Torin2 is a potent, selective and orally available inhibitor of mTOR with EC50 value of 0.25nM [1].
Torin2 is a highly potent and selective mTOR inhibitor. It is easier to produce than its lead compound Torin1 and displays improved pharmacokinetic properties. Torin2 is predicted to engage in hydrogen bonds with V2240 and Y2225 of a homology model of mTOR. It also form two hydrogen bonds between the aniline amino group of it with D2195 and D2357, making it more potent than Torin1. Besides that, Torin2 shows excellent overall selectivity and has strong binding to mTOR, CSNK1E, several PI3Ks, CSF1R and MKNK2. Torin2 exerts 800-fold cellular selectivity relative to inhibition of PI3K and other protein kinases. Moreover, Torin2 shows good bioavailability and exposure in vivo [1].
References:
[1] Liu Q, Wang J, Kang S A, et al. Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl) phenyl) benzo [h][1, 6] naphthyridin-2 (1 H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer. Journal of medicinal chemistry, 2011, 54(5): 1473-1480.
Average Rating: 5
(Based on Reviews and 5 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *